Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H56:IC31 in Reducing the Rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis
NCT03512249Phase 2Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jan 2019
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of AERAS-456 in Tuberculosis (TB), sponsored by International AIDS Vaccine Initiative. Started Jan 2019; status: completed.
02
Drugs
AERAS-456
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03512249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512249.